SLDB · Solid Biosciences Inc.
$9.10
-0.10 (-1.09%)
At close · Aug 17
Market Cap
$986.47M
Shares
107.23M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Alexander Cumbo | President and Chief Executive Officer | $5,223,442 |
| David Tyronne Howton | Chief Operating Officer and Secretary | $2,588,827 |
| Gabriel Brooks | M.D., Chief Medical Officer | $2,328,156 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Alexander Cumbo | President and Chief Executive Officer | $4,869,909 |
| David Tyronne Howton | Chief Operating Officer and Secretary | $2,563,014 |
| Gabriel Brooks | M.D., Chief Medical Officer | $2,071,372 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Carl Morris | Ph.D., Former Chief Scientific Officer, Neuromuscular | $1,559,449 |
| Kevin Tan | Chief Financial Officer | $1,346,305 |
| Alexander Cumbo | President and Chief Executive Officer | $918,630 |
| David Tyronne Howton | Chief Operating Officer and Secretary | $648,880 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Ilan Ganot | Former President and Chief Executive Officer | $2,205,508 |
| Alexander Cumbo | President and Chief Executive Officer | $2,200,212 |
| Erin Powers Brennan | Former Chief Legal Officer and Secretary | $1,339,762 |
| David Tyronne Howton | Chief Operating Officer, General Counsel and Secretary | $1,017,870 |
| Carl Morris | Ph.D., Former Chief Scientific Officer, Neuromuscular | $873,723 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Ilan Ganot | Former President and Chief Executive Officer | $3,293,809 |
| Erin Powers Brennan | Former Chief Legal Officer and Secretary | $2,878,244 |
| Joel Schneider | Ph.D., Chief Operating Officer | $1,702,761 |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| Ilan Ganot | President and Chief Executive Officer | $1,481,002 |
Fiscal 2019
| Executive | Role | Total |
|---|---|---|
| Ilan Ganot | President and Chief Executive Officer | $3,335,929 |
| Jorge Quiroz | M.D., Former Chief Medical Officer | $1,541,208 |
| Alvaro Amorrortu | Former Chief Operating Officer | $1,523,308 |
Fiscal 2018
| Executive | Role | Total |
|---|---|---|
| Ilan Ganot | President and Chief Executive Officer | $5,983,770 |
| Alvaro Amorrortu | Former Chief Operating Officer | $2,842,736 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Ilan Ganot | Class I Director | Appointed | 2026-04-10 |
| Ilan Ganot | Class III Director | Resigned | 2026-04-10 |
| Sukumar Nagendran | Class I director | Appointed | 2025-06-13 |
| Alexander Cumbo | Class I director | Appointed | 2025-06-13 |
| Ian Smith | Class III director | Appointed | 2024-06-11 |
| Georgia Keresty | Class III director | Appointed | 2024-06-11 |
| Ilan Ganot | Class III director | Appointed | 2024-06-11 |
| Rajeev Shah | member of the Board | Resigned | 2024-06-11 |
| Martin Freed | Class III director | Appointed | 2024-06-11 |
| Adam Koppel | member of the Company's Board of Directors | Resigned | 2024-06-11 |
| Lynne Sullivan | Class II director | Appointed | 2023-06-09 |
| Adam Stone | Class II director | Appointed | 2023-06-09 |
| Adam Koppel | Class II director | Appointed | 2023-06-09 |
| Clare Kahn | Class II director | Appointed | 2023-06-09 |
| Jennifer Marlowe | Chief Scientific Officer | Appointed | 2023-05-22 |
| Carl Morris | Chief Scientific Officer, Neuromuscular | Resigned | 2023-05-22 |
| Kevin Tan | Chief Financial Officer | Appointed | 2023-01-09 |
| Erin Powers Brennan | Chief Legal Officer and Secretary | Resigned | 2022-12-05 |
| Ilan Ganot | Chief Executive Officer and President | Resigned | 2022-12-05 |
| Adam Koppel, M.D., Ph.D. | member of the Board | Appointed | 2022-12-05 |
| Alexander (Bo) Cumbo | member of the Board | Appointed | 2022-12-05 |
| Alexander (Bo) Cumbo | President and Chief Executive Officer | Appointed | 2022-12-05 |
| Bo Cumbo | board of directors | Appointed | 2022-09-30 |
| Bo Cumbo | President and Chief Executive Officer | Appointed | 2022-09-30 |
| Adam Koppel | board of directors | Appointed | 2022-09-30 |
Key facts
CIK
1707502
CUSIP
83422E204
13F (30d)
154 filings
150 filers
Visit website
Investor relations